Mission Statement

Primera Therapeutics is focused on addressing the root cause of mitochondrial diseases by developing a first-in-class gene editing platform to target inherited mutant mitochondrial DNA. Primera’s first approach uses a fully customizable TALE-based system to specifically target a stretch of DNA and a molecule that can correct the mutant DNA in the mitochondrial genome. This enables precision gene editing to be deployed at the mitochondrial level for the first time. By leveraging an innovative toolbox with the support of key strategic partners, Primera seeks to accelerate the development of genetic mitochondrial disease therapies and quickly aid this undeserved patient population. Primera will work directly with Cellectis, Children’s Hospital of Philidelphia (CHOP), Mayo Clinic, the United Mitochondrial Disease Foundation (UMDF) and other collaborators, to bring a therapy to clinic as fast as possible.

On the web